CenterBook Partners LP Acquires 38,282 Shares of Soleno Therapeutics, Inc. $SLNO

CenterBook Partners LP boosted its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 156.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,794 shares of the company’s stock after purchasing an additional 38,282 shares during the period. CenterBook Partners LP owned approximately 0.12% of Soleno Therapeutics worth $4,245,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Soleno Therapeutics by 12.8% in the third quarter. Vanguard Group Inc. now owns 2,807,149 shares of the company’s stock worth $189,763,000 after buying an additional 319,317 shares during the period. Westfield Capital Management Co. LP grew its position in Soleno Therapeutics by 18.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,429,756 shares of the company’s stock worth $119,785,000 after acquiring an additional 218,511 shares during the last quarter. State Street Corp increased its stake in Soleno Therapeutics by 20.2% in the 2nd quarter. State Street Corp now owns 1,404,983 shares of the company’s stock worth $117,709,000 after purchasing an additional 235,784 shares during the period. Geode Capital Management LLC lifted its position in Soleno Therapeutics by 46.6% in the second quarter. Geode Capital Management LLC now owns 902,396 shares of the company’s stock valued at $75,611,000 after purchasing an additional 286,660 shares during the last quarter. Finally, Emerald Advisers LLC lifted its position in Soleno Therapeutics by 19.2% in the second quarter. Emerald Advisers LLC now owns 672,908 shares of the company’s stock valued at $56,376,000 after purchasing an additional 108,427 shares during the last quarter. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Soleno Therapeutics Trading Up 0.3%

NASDAQ:SLNO opened at $38.61 on Thursday. The company has a 50-day moving average price of $44.04 and a 200-day moving average price of $55.43. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -20.98 and a beta of -3.16. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. Soleno Therapeutics, Inc. has a 12 month low of $36.67 and a 12 month high of $90.32.

Wall Street Analyst Weigh In

SLNO has been the topic of several recent analyst reports. Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a report on Monday, January 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Robert W. Baird set a $107.00 price objective on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. Wall Street Zen raised shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Wells Fargo & Company reissued an “overweight” rating and issued a $114.00 target price (up from $106.00) on shares of Soleno Therapeutics in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $110.62.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.